312 related articles for article (PubMed ID: 28013198)
1. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
Moots RJ; Sebba A; Rigby W; Ostor A; Porter-Brown B; Donaldson F; Dimonaco S; Rubbert-Roth A; van Vollenhoven R; Genovese MC
Rheumatology (Oxford); 2017 Apr; 56(4):541-549. PubMed ID: 28013198
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
Navarro-Millán I; Singh JA; Curtis JR
Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
[TBL] [Abstract][Full Text] [Related]
5. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
6. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients.
Nakajima T; Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ito H; Yamamoto W; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Ohmura K; Matsuda S; Morinobu A
Rheumatol Int; 2022 Nov; 42(11):1983-1991. PubMed ID: 34241658
[TBL] [Abstract][Full Text] [Related]
9. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.
McInnes IB; Thompson L; Giles JT; Bathon JM; Salmon JE; Beaulieu AD; Codding CE; Carlson TH; Delles C; Lee JS; Sattar N
Ann Rheum Dis; 2015 Apr; 74(4):694-702. PubMed ID: 24368514
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.
Narváez J; Magallares B; Díaz Torné C; Hernández MV; Reina D; Corominas H; Sanmartí R; LLobet JM; Rodriguez de la Serna A; Nolla JM
Semin Arthritis Rheum; 2016 Feb; 45(4):386-90. PubMed ID: 26254548
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
Navarro G; Taroumian S; Barroso N; Duan L; Furst D
Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
14. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
16. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
[TBL] [Abstract][Full Text] [Related]
17. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
Keystone EC; Anisfeld A; Ogale S; Devenport JN; Curtis JR
J Rheumatol; 2014 Feb; 41(2):216-26. PubMed ID: 24429164
[TBL] [Abstract][Full Text] [Related]
18. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.
Wright HL; Cross AL; Edwards SW; Moots RJ
Rheumatology (Oxford); 2014 Jul; 53(7):1321-31. PubMed ID: 24609058
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
